ArticleBlood2006
Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death.
Article in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Galectin network in osteoarthritis: galectin-4 programs a pathogenic signature of gene and effector expression in human chondrocytes in vitro.Histochemistry and cell biology · 2022Article
- Spatiotemporal regulation of galectin-1-induced T-cell death in lamina propria from Crohn's disease and ulcerative colitis patients.Apoptosis : an international journal on programmed cell death · 2021Article
- How galectins have become multifunctional proteins.Histology and histopathology · 2020Review
- Altered Cell Surface N-Glycosylation of Resting and Activated T Cells in Systemic Lupus Erythematosus.International journal of molecular sciences · 2019Article
- From glycophenotyping by (plant) lectin histochemistry to defining functionality of glycans by pairing with endogenous lectins.Histochemistry and cell biology · 2018Review
- Dysfunctional immunoregulation in human liver allograft rejection associated with compromised galectin-1/CD7 pathway function.Cell death & disease · 2018Article
- Galectin-9 binds to O-glycans on protein disulfide isomerase.Glycobiology · 2017Article
- Galectins: their network and roles in immunity/tumor growth control.Histochemistry and cell biology · 2017Review
- Key regulators of galectin-glycan interactions.Proteomics · 2016Review
- Differentiation-related glycan epitopes identify discrete domains of the muscle glycocalyx.Glycobiology · 2016Article
- Galectin-1 regulates tissue exit of specific dendritic cell populations.The Journal of biological chemistry · 2015Article
- Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer.Frontiers in oncology · 2015Review
- Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.Blood · 2012Article
- T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.Annals of the New York Academy of Sciences · 2012Review
- Mucin O-glycan branching enzymes: structure, function, and gene regulation.Advances in experimental medicine and biology · 2011Article
- Mutational tuning of galectin-3 specificity and biological function.The Journal of biological chemistry · 2010Article
- N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death.The Journal of biological chemistry · 2010Article
- Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation.Nature reviews. Immunology · 2009Review
- T cell apoptosis at the maternal-fetal interface in early human pregnancy, involvement of galectin-1.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Mammalian glycosylation in immunity.Nature reviews. Immunology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Neoplastic T cells in mycosis fungoides (MF) are resistant to apoptotic agents, including galectin-1 that is abundant in skin. Although MF cells are typically CD7-, and thus galectin-1 resistant, CD7+ HH cells, derived from a patient with MF, were also resistant to galectin-1. HH cells demonstrate altered cell surface glycosylation, with loss of core 2 O-glycan ligands for galectin-1 created by core 2 beta1,6-N-acetylglucosaminyltransferase (C2GnT-I). Loss of core 2 O-glycans on tumor cells was also seen in primary CD7+ MF lesions. Surprisingly, HH cells are heterozygous for a C2GnT-I point mutation, yet this mutation resulted in a dramatic reduction in cellular glycosyltransferase activity. Expression of wild-type C2GnT-I in human HH cells, or murine lymphoma cells that lack C2GnT-I, restored core 2 O-glycan expression and susceptibility to galectin-1, whereas mutant enzyme lacked activity and did not restore core 2 O-glycan expression or susceptibility to galectin-1. Mutant enzyme did not have a dominant negative effect by affecting dimerization or activity of wild-type enzyme; rather, C2GnT-I haploinsufficiency is sufficient for loss of core 2 O-glycan expression and galectin-1 resistance. Thus, glycosyltransferase haploinsufficiency results in altered cellular glycosylation and resistance to cell death, identifying a new survival mechanism for T-lymphoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.